Literature DB >> 20520634

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.

F Dicker, C Haferlach, J Sundermann, N Wendland, T Weiss, W Kern, T Haferlach, S Schnittger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20520634     DOI： 10.1038/leu.2010.124

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  52 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

2.  Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion.

Authors:  Ruibin Xi; Angela G Hadjipanayis; Lovelace J Luquette; Tae-Min Kim; Eunjung Lee; Jianhua Zhang; Mark D Johnson; Donna M Muzny; David A Wheeler; Richard A Gibbs; Raju Kucherlapati; Peter J Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

4.  Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Authors:  Manja Meggendorfer; Andreia de Albuquerque; Niroshan Nadarajah; Tamara Alpermann; Wolfgang Kern; Kimberly Steuer; Karolína Perglerová; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

5.  TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Authors:  Xiaopeng Tian; Yang Xu; Jia Yin; Hong Tian; Suning Chen; Depei Wu; Aining Sun
Journal:  Int J Hematol       Date:  2014-05-24       Impact factor: 2.490

6.  Mutations of ASXL1 and TET2 in aplastic anemia.

Authors:  Jinbo Huang; Meili Ge; Shihong Lu; Jun Shi; Xingxin Li; Jizhou Zhang; Min Wang; Wei Yu; Yingqi Shao; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

Review 7.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

8.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Authors:  Jie Sun; Xin He; Yinghui Zhu; Zonghui Ding; Haojie Dong; Yimei Feng; Juan Du; Hanying Wang; Xiwei Wu; Lei Zhang; Xiaochun Yu; Allen Lin; Tinisha McDonald; Dandan Zhao; Herman Wu; Wei-Kai Hua; Bin Zhang; Lifeng Feng; Kaoru Tohyama; Ravi Bhatia; Philipp Oberdoerffer; Yang Jo Chung; Peter D Aplan; Jacqueline Boultwood; Andrea Pellagatti; Samer Khaled; Marcin Kortylewski; Flavia Pichiorri; Ya-Huei Kuo; Nadia Carlesso; Guido Marcucci; Hongchuan Jin; Ling Li
Journal:  Cell Stem Cell       Date:  2018-08-23       Impact factor: 24.633

Review 9.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 10.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.